Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prioritization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Prioritization. Displaying page 1 of 1.
    EudraCT Number: 2016-000160-42 Sponsor Protocol Number: M2016 Start Date*: 2016-05-17
    Sponsor Name:UK für Anästhesiologie und allgemeine Intensivmedizin
    Full Title: Effect of inhaled budenoside on the incidence and severity of Acute Mountain Sickness at 4559 m
    Medical condition: Healthy volunteer trial at 4459m to investigate the effect of inhaled budenoside on the incidence and severity of Acute Mountain Sickness.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004863 10020045 High altitude illness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005166-22 Sponsor Protocol Number: M2018 Start Date*: 2018-03-26
    Sponsor Name:UK für Anästhesiologie und allgemeine Intensivmedizin
    Full Title: Effect of acetazolamide on the incidence of high altitude pulmonary edema at 4559 m
    Medical condition: Healthy volunteer trial at 4459m to investigate the effect of acetazolamide on the incidence of high altitude pulmonary edema.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10020045 High altitude illness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000592-36 Sponsor Protocol Number: CGRPAMS03 Start Date*: 2023-07-10
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Calcitonin Gene-Related Peptide Receptor Antagonists for Prevention of Acute Mountain Sickness
    Medical condition: Acute Mountain Sickness (AMS) is a constellation of symptoms (headache, anorexia, nausea, vomiting, lightheadedness, and fatigue) occuring in unacclimatized mountaineers ascending too fast, too high
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10020045 High altitude illness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005086-41 Sponsor Protocol Number: B1030-101 Start Date*: 2022-12-06
    Sponsor Name:SOTIO Biotech Inc
    Full Title: A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T cells in Subjects With Advanced GPC3-Positive Solid Tumors.
    Medical condition: Histologically confirmed advanced unresectable or metastatic hepatocellular carcinoma (HCC), squamous cell carcinoma (SCC) of the lung, myxoid/round cell liposarcoma, or Merkel cell carcinoma (MCC)...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077738 Hepatocellular carcinoma metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025120 Lung squamous cell carcinoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073139 Round cell liposarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002055-10 Sponsor Protocol Number: PURE-01 Start Date*: 2020-07-06
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: PURE-01 – An open label, single-arm, phase 2 study of neoadjuvant pembrolizumab (MK-3475) before cystectomy for patients with muscle-invasive urothelial bladder cancer.
    Medical condition: muscle-invasive urothelial bladder cancer
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Nov 28 07:43:50 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA